Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations

August 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones.

This finding was reported in the article “Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes”, which was published online in August 2018 by the medical journal JAMA Internal Medicine.

Among the results stated by medical researchers involved with a recently concluded retrospective cohort study and reported in this medical journal article:

[N]ew use of sodium-glucose cotransporter 2 inhibitors was associated with a statistically significant increased risk of amputation compared with use of metformin, sulfonylureas, and thiazolidinediones.

We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have had lower limb amputations (legs, feet, toes) while using Invokana, Jardiance, Farxiga, or any of these other SGLT-2 inhibitors: Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet.

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for: